Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134335) titled 'UBT251 Injection Phase II Clinical Study (CKD)' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Condition:
Obesity &Amp
Overweight
Chronic Kidney Disease
Intervention:
Drug: UBT251
Drug: UBT251
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: July 11, 2025
Target Sample Size: 180
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT071...